# The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

> **NCT06176911** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 124 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Danazol

## Key facts

- **NCT ID:** NCT06176911
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-05
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-07-15
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176911, "The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06176911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*